^
    12ms
    ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk (clinicaltrials.gov)
    P=N/A; Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: Jul 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    Oncoguard™ Liver
    over1year
    Clinical Utility of Oncoguard Liver Test to Further Classify Indeterminate Liver Lesions in a High Risk Cirrhotic Population at Risk for HCC [Board No. A278] (ATC 2023)
    The Oncoguard Liver test may provide an additional tool to aid in the diagnosis of indeterminate liver lesions in patients at risk for HCC whom do not meet radiologic criteria for HCC (LR 5) and whom do not have an elevated AFP . This real-world single center retrospective study demonstrates similar specificities and sensitivities to the previously reported case control validation studies. OGL is a clinically useful non-invasive blood test which may help avoid critical delay in diagnosis of HCC and also avoid additional and potential challenging biopsies of indeterminate lesions.
    Clinical
    |
    AFP elevation
    |
    Oncoguard™ Liver
    over2years
    Case Report: Multitarget HCC Blood Test in the Early Detection of HCC (ACG 2022)
    "This patient demonstrates benefits of early diagnosis; less invasive treatment options leading to cure of HCC. How to use the mt-HBT in post HCC cure needs further investigation, but this case demonstrates the benefit of the mt-HBT."
    Clinical
    |
    AFP (Alpha-fetoprotein)
    |
    Oncoguard™ Liver
    over2years
    ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk (clinicaltrials.gov)
    P=N/A | N=3000 | Recruiting | Sponsor: Exact Sciences Corporation | Trial completion date: Jul 2023 ➔ Oct 2025 | Trial primary completion date: Jul 2022 ➔ Jul 2023
    Trial completion date • Trial primary completion date
    |
    Oncoguard™ Liver
    3years
    ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk (clinicaltrials.gov)
    P=N/A; N=3000; Recruiting; Sponsor: Exact Sciences Corporation
    New trial • Clinical
    |
    Oncoguard™ Liver